MARTIN TOBI
Medical Practice in Southfield, MI
License number
Pennsylvania MD428700
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Southfield, MI 48075
Pennsylvania
Pennsylvania
Personal information
See more information about MARTIN TOBI at radaris.comName
Address
Phone
17159 Alta Vista Dr, Southfield, MI 48075
21310 Constitution St, Southfield, MI 48076
21310 Constitution, Sunfield, MI 48076
Professional information
See more information about MARTIN TOBI at trustoria.com
Process For Producing Monoclonal Antibodies Which Specifically Bind To Benign Colonic Adenomatous Polyps Of Human Origin And Hybridomas And Monoclonal Antibodies Produced By Said Process
Process For Producing Monoclonal Antibodies Which Specifically Bind To Benign Colonic Adenomatous Polyps Of Human Origin And Hybridomas And Monoclonal Antibodies Produced By Said Process
US Patent:
5244801, Sep 14, 1993
Filed:
Dec 28, 1989
Appl. No.:
7/458498
Inventors:
Martin Tobi - Southfield MI
International Classification:
C12N 520, C12N 1502, C12P 2108, C07K 1528
US Classification:
43524027
Abstract:
Monoclonal antibodies manifesting specific reactivity to benign adenomatous polyps of the human colon are produced. Hybridoma technology was utilized to produce immunoglobulin producing cell lines. Splenic lymphocytes from mice, immunized with a membrane fraction derived from human tubular adenomatous colonic polyps, were fused with a mouse non immunoglobulin secreting myeloma cell line (NS-1). Screening of hybridoma culture supernatant for positive reactivity with adenomatous colonic polyp extract, and negative activity with extracts from normal liver and spleen allowed for selection of desired immunoglobulin producing cultures. Further screening of expanded cultures with extracts of colorectal cancer, apparently normal mucosa adjacent to the cancer, and a variety of normal human extracts allowed further distinctions in binding reactivity. One such selected cell line produced a monoclonal antibody designated Adnab-9 selected on this basis. Adnab-9 was reacted with colonic-washing effluent derived from patients undergoing routine precolonoscopic bowel cleansing and the resultant mean binding activity in the effluent of patients proved to have a colorectal cancer was significantly elevated with respect to those with an apparently normal colon.